

RESULT 3

AAB92553

ID AAB92553 standard; protein; 464 AA.

XX

AC AAB92553;

XX

DT 26-JUN-2001 (first entry)

XX

DE Human protein sequence SEQ ID NO:10739.

XX

KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.

XX

OS Homo sapiens.

XX

PN EP1074617-A2.

XX

PD 07-FEB-2001.

XX

PF 28-JUL-2000; 2000EP-00116126.

XX

PR 29-JUL-1999; 99JP-00248036.

PR 27-AUG-1999; 99JP-00300253.

PR 11-JAN-2000; 2000JP-00118776.

PR 02-MAY-2000; 2000JP-00183767.

PR 09-JUN-2000; 2000JP-00241899.

XX

PA (HELI-) HELIX RES INST.

XX

PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

XX

DR WPI; 2001-318749/34.

XX

PT Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.

XX

PS Claim 8; SEQ ID NO 10739; 2537pp + Sequence Listing; English.

XX

CC The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises:

CC (a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesising polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the

CC present invention
 XX
 SQ Sequence 464 AA;

Query Match 99.6%; Score 2431; DB 4; Length 464;
 Best Local Similarity 99.6%; Pred. No. 9.2e-239;
 Matches 462; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	1	MPKKAKPTGSGKEEGPAPCKQMKLEAAGGPSALNFDSPSSLFESLISPIKTETFFKEFWE	60
Db	1	MPKKAKPTGSGKEEGPAPCKQMKLEAAGGPSALNFDSPSSLFESLISPIKTETFFKEFWE	60
Qy	61	QKPLLIQRDDPALATYYGSLFKLTDLKS LCSRGMYYGRDVNVCRCVNGKKKVLNKDGKAH	120
Db	61	QKPLLIQRDDPALATYYGSLFKLTDLKS LCSRGMYYGRDVNVCRCVNGKKKVLNKDGKAH	120
Qy	121	FLQLRKDFDQKRATI QFHQPQRFKDELWRIQEKLECYFGSLVGSNVYITPAGSQGLPPHY	180
Db	121	FLQLRKDFDQKRATI QFHQPQRFKDELWRIQEKLECYFSSLVGSNVYITPAGSQGLPPHY	180
Qy	181	DDVEVFILQLEGEKHWRLYHPTVPLAREYSVEAEERIGRPVHEFMLKPGDLLYFPRGTIH	240
Db	181	DDVEVFILQLEGEKHWRLYHPTVPLAREYSVEAEERIGRPVHEFMLKPGDLLYFPRGTIH	240
Qy	241	QADTPAGLAHSTHVTISTYQNNSWGDFLLDTISGLVFDTAKEDVELRTGI PRQLLLVEST	300
Db	241	QADTPAGLAHSTHVTISTYQNNSWGDFLLDTISGLVFDTAKEDVELRTGI PRQLLLVEST	300
Qy	301	TVATRRLSGFLRTLADRLEGTKELLSSDMKKDFIMHRLPPYSAGDGAELSTPGGKLPRLD	360
Db	301	TVATRRLSGFLRTLADRLEGTKELLSSDMKKDFIMHRLPPYSAGDGAELSTPGGKLPRLD	360
Qy	361	SVVRLQFKDHIVLTVLPDQDQSDEAQEKMVYIYHSLKNSRETHMMGNEEETEFHGLRFPL	420
Db	361	SVVRLQFKDHIVLTVLPDQDQSDTQEKMVYIYHSLKNSRETHMMGNEEETEFHGLRFPL	420
Qy	421	SHLDALKQIWNSPAISVKDLKLTDEEKESLVLSLWTECLIQVV	464
Db	421	SHLDALKQIWNSPAISVKDLKLTDEEKESLVLSLWTECLIQVV	464